I wouldn't get your hopes up. Amgen evaluated the initial data and though it wasn't good enough. The fact they would rather flush $65m already invested down the drain rather than put another dime in NEO says a lot about whether the program will be a success. The jury is out, ADXS' science through years of trials and clincial data has fallen short of expectations especially in context of the rapid development of more promising tech.
News 
Market Data 
Discover 
